Acadia Pharmaceuticals (ACAD) Equity Ratio (2016 - 2025)
Historic Equity Ratio for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to 0.69.
- Acadia Pharmaceuticals' Equity Ratio rose 1665.93% to 0.69 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.69, marking a year-over-year increase of 1665.93%. This contributed to the annual value of 0.62 for FY2024, which is 702.2% up from last year.
- Latest data reveals that Acadia Pharmaceuticals reported Equity Ratio of 0.69 as of Q3 2025, which was up 1665.93% from 0.67 recorded in Q2 2025.
- Acadia Pharmaceuticals' 5-year Equity Ratio high stood at 0.79 for Q3 2021, and its period low was 0.54 during Q1 2024.
- Its 5-year average for Equity Ratio is 0.66, with a median of 0.68 in 2025.
- As far as peak fluctuations go, Acadia Pharmaceuticals' Equity Ratio crashed by 1984.6% in 2023, and later surged by 2452.86% in 2025.
- Quarter analysis of 5 years shows Acadia Pharmaceuticals' Equity Ratio stood at 0.77 in 2021, then decreased by 11.83% to 0.68 in 2022, then decreased by 15.37% to 0.58 in 2023, then grew by 7.02% to 0.62 in 2024, then grew by 11.72% to 0.69 in 2025.
- Its Equity Ratio was 0.69 in Q3 2025, compared to 0.67 in Q2 2025 and 0.68 in Q1 2025.